Newmont Corporation vs Oruka Therapeutics Inc. Common Stock — how do they compare? Newmont Corporation trades at $112.29 (market cap $121.80B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Newmont Corporation is far larger — about 23.5× Oruka Therapeutics Inc. Common Stock's market cap, and Newmont Corporation pays a 0.9% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 59 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| NEM | ORKA | |
|---|---|---|
Market Cap | $121.80B | $5.18B |
Volume | 4,383,120 | 490,798 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $113.08 |
52-Week Low | $78.63 | $26.19 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $118.39B | $4.31B |
Dividend Yield | 0.9% | — |
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $111.56, down 4.77% over the past 24 hours, with strong fundamental performance including record free cash flow of $5.3 billion in H1 2026 and three consecutive quarterly earnings beats. The stock shows a bullish technical signal with moving averages supporting upward momentum, while maintaining attractive valuation metrics including a P/E of 14.58 and EV/EBITDA of 7.38. Recent news highlights the company's focus on per-share growth and operational improvements amid constructive gold market conditions.
Newmont presents a compelling investment case with robust profitability (33.36% net margin), strong analyst consensus (76% buy ratings), and 22% upside to the $136.83 price target. Key risks include gold price volatility and execution of growth initiatives, but the company's record cash flow generation and improving balance sheet provide solid foundation for continued shareholder value creation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →